Most Read Articles
one year ago
Age at onset significantly influences long-term clinical outcomes and health-related quality of life in paediatric ischaemic stroke survivors based on a study.
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, one year ago
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

TNFi monotherapy initiation in PsA patients decline despite efficacy

3 months ago

There have been significant changes in the treatment patterns among patients with psoriatic arthritis (PsA) from 2004 to 2012, according to a recent study.

Patients remain persistent with the use of tumor necrosis factor inhibitor (TNFi) monotherapy, but physicians are not more likely to initiate it despite an increase in clinical evidence over this study period supporting its effectiveness.

To improve understanding of current practices in the treatment management of patients with PsA, an observational study was conducted based on data from the Corrona registry of adult patients with PsA in North America collected between 1 January 2004 and 31 December 2012.

Researchers divided the participants (n=520) into three therapy cohorts: TNFi monotherapy (n=190), methotrexate (MTX) monotherapy (n=217) and TNFi-MTX combination therapy (n=113). Patients were further classified into three study periods to understand changes over time: 2004 to 2006 (n=110), 2007 to 2009 (n=192) and 2010 to 2012 (n=218).

For the analysis, researchers collected data on persistence, discontinuation, restarting, switching, adding/dropping therapy and dose stretching.

A decrease in the proportion of patients initiating TNFi monotherapy occurred over time, but the proportion initiating combination therapy remained constant.

Participants who were persistent also decreased over time across all therapy cohorts, but the percentage of patients remained higher in TNFi monotherapy than in other therapy groups. In addition, the duration of persistence declined over time.

Compared with patients in the TNFi monotherapy cohort, those initiating MTX monotherapy were more likely to add therapy, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
one year ago
Age at onset significantly influences long-term clinical outcomes and health-related quality of life in paediatric ischaemic stroke survivors based on a study.
3 months ago
New drug applications approved by US FDA as of 1 - 15 February 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, one year ago
Valsartan/sacubitril (formerly LCZ696), recently approved by the US Food and Drug Administration for treating heart failure, may also be beneficial for reducing blood pressure (brachial and central aortic pressure) as well as arterial stiffness compared with angiotensin receptor blocker olmesartan.
one year ago
New drug applications approved by US FDA as of 16 - 31 Dec 2015 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.